IO102-IO103

Phase 3Small molecule

IIO Biotech

IO102-IO103 is one of 130 small molecule programs targeting First-line Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-Line TreatmentActive, not recruiting

PembrolizumabRecruiting

MelanomaActive, not recruiting

First-Line TreatmentPhase 2

Active, not recruiting

PembrolizumabPhase 2

Recruiting

MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

191 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

95 2

Opdivo

Mekinist

45 4

Cotellic

Roche

Phase 3

21 5

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 3

39 6

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 7

Taxol

Teva

Phase 3

13 8

Tecentriq

Roche

Phase 3

11 9

Lenvima

Eisai

Phase 3

9 10

Libtayo

Regeneron

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Pembrolizumab

NCT05280314

Q3 2027

Phase 3Active, not recruiting

Melanoma

NCT05155254

Clinical

Trials by Indication[1]

First-line Treatment1 trial

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Active, not recruiting·IIO Biotech·Phase 2·NCT05077709·63 enrolled

Melanoma1 trial

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting·IIO Biotech·Phase 3·NCT05155254·407 enrolled

Pembrolizumab1 trial

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting·IIO Biotech·Phase 2·NCT05280314·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for IO102-IO103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IO102-IO103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IO102-IO103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IO Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIO Biotech

IO102-IO103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

First-line Treatment1 trial

Melanoma1 trial

Pembrolizumab1 trial

References

Drug Info

Quick Facts

Related News